Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HepCgen genotyping service helps fight Hepatitis C, a "silent epidemic"

22.07.2003


Genotyping provides route to tailored treatment at lower cost with less side effects

A new centralised genotyping service that enables clinicians to differentiate between types of hepatitis C infections is poised to improve treatment for patients with Hepatitis C, a severely under treated viral infection in the UK. The new service, available through HepCgen will allow clinicians to tailor costly interferon-based treatment regimes to the patients’ viral genotype, thus lowering costs and side effects.

Although five times more prevalent than HIV, most cases of Hepatitis C go undetected, prompting the phrase ‘the silent epidemic’, therefore it is important that, once identified, diagnosis and treatment commence without delay. “HepCgen’s centralised Hepatitis C genotyping service allows hospitals throughout the UK extremely rapid access to this important information, without the need for an expensive and time consuming in-house genotyping set up”, said Paul Colford, CEO of HepCgen.



Through early identification of patients with genotype 1, or non-1, HepCgen is able to distinguish patients that may require lower doses for shorter periods of time. This knowledge not only has obvious benefits to the patient by reducing medication and associated side effects, but also provides a significant cost saving to healthcare funders: HepCgen founder Dr William Rosenberg estimates a saving to the NHS of half a billion pounds a year if doctors routinely use this service.

HepCgen regards cost of treatment as a significant factor in the number of patients undergoing treatment for Hepatitis C and Dr Rosenberg notes, “Of the 400,000 cases in the UK only about 20,000-30,000 are in secondary care and of those, only some 2,000 cases are being treated, because the NHS won’t release funding for treatment.”

Further evidence of the importance placed on genotyping in the treatment of hepatitis C came with Roche’s announcement on 18th July of the European Commission’s approval of a new label for PEGASYS, Roche’s flagship treatment for the hepatitis C virus. The approval came as a result of a pivotal study by Roche, demonstrating that the duration of combination therapy and dose of Copegus (ribavirin) for chronic hepatitis C patients depends on viral genotype. Dr. Rosenberg continues, “We have demonstrated similar data with the Schering-Plough therapy, among others. The importance of identifying genotype in the treatment of Hepatitis C is becoming rapidly accepted. This recognition by the European Commission is strong additional testimony.”

“HepCgen currently provides its proprietary services to over 20 centres in the UK, most of which are reimbursed by the major pharmaceutical companies involved in Hepatitis C”, stated Mr Colford. “We would like to expand our services throughout Europe, as countries like Italy, Germany, and France are treating over five times the number of patients the UK chooses to, and will tremendously benefit by either using HepCgen services or licensing this technology. ”

HepCgen Ltd was recently spun out of the University of Southampton and specialises in diagnostics and treatments for chronic liver disease. Dr. Spike Willcocks, IP2IPO adds, “HepCgen is a very exciting opportunity in our portfolio, whose technology meets a now widely recognised medical need, and this step demonstrates the increasing value of the Company. Further development in this area could be rapidly accelerated with additional financing in the near future.”

For more information, please contact:

At the company

Paul Colford, CEO HepCgen Ltd, paul.colford@hepcgen.com
Dr William Rosenberg, wmr@soton.ac.uk

Media enquiries

Dr. Spike Willcocks, IP2IPO, spike.wilcocks@ip2ipo.com
Sue Charles, Northbank Communications, s.charles@northbankcommunications.com
James Parkinson, Northbank Communications, j.parkinson@northbankcommunications.com

Louise Johnson | alfa
Further information:
http://www.hepcgen.com

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Midwife and signpost for photons

11.12.2017 | Physics and Astronomy

How do megacities impact coastal seas? Searching for evidence in Chinese marginal seas

11.12.2017 | Earth Sciences

PhoxTroT: Optical Interconnect Technologies Revolutionized Data Centers and HPC Systems

11.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>